Compare ASTH & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | AMLX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2015 | 2021 |
| Metric | ASTH | AMLX |
|---|---|---|
| Price | $37.94 | $34.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $34.86 | $21.56 |
| AVG Volume (30 Days) | 447.2K | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $519,907,752.00 | $380,786,000.00 |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $10.78 | N/A |
| P/E Ratio | $55.67 | ★ N/A |
| Revenue Growth | 45.90 | ★ 1612.94 |
| 52 Week Low | $18.08 | $9.15 |
| 52 Week High | $51.60 | $41.14 |
| Indicator | ASTH | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 71.92 |
| Support Level | $36.47 | $12.54 |
| Resistance Level | $40.35 | $41.14 |
| Average True Range (ATR) | 1.91 | 2.27 |
| MACD | 0.24 | 0.63 |
| Stochastic Oscillator | 59.71 | 75.83 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.